November 2023 in “British Journal of Dermatology” Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.
2 citations
,
January 2019 in “Skin appendage disorders” This article reports a case of frontal fibrosing alopecia in its early inflammatory stage that responded positively to intralesional steroid treatment.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.
October 2025 in “Journal of Clinical Medicine” This study found that in patients with severe alopecia areata, those who responded early to baricitinib treatment typically had a lower baseline Severity of Alopecia Tool score, shorter disease duration, and higher erythrocyte sedimentation rate, suggesting these factors may predict therapeutic success.
March 2026 in “Expert Opinion on Pharmacotherapy” This review highlights that JAK inhibitors have transformed severe alopecia areata treatment by disrupting disease signaling, emphasizing the need for strategies to address non-responders and manage treatment discontinuation.